SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

AMBROSIO, Maria Rosaria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.798
AS - Asia 8.114
EU - Europa 6.292
SA - Sud America 1.423
AF - Africa 135
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 8
Totale 30.781
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.446
SG - Singapore 3.518
CN - Cina 2.341
DE - Germania 2.278
BR - Brasile 1.217
IT - Italia 926
UA - Ucraina 840
HK - Hong Kong 780
RU - Federazione Russa 527
GB - Regno Unito 476
TR - Turchia 458
VN - Vietnam 453
FI - Finlandia 395
SE - Svezia 236
PL - Polonia 207
MX - Messico 168
CA - Canada 155
ID - Indonesia 118
IN - India 105
FR - Francia 102
AR - Argentina 87
NL - Olanda 78
ZA - Sudafrica 67
JP - Giappone 64
BD - Bangladesh 62
ES - Italia 53
IQ - Iraq 42
LT - Lituania 38
BE - Belgio 34
AT - Austria 33
EC - Ecuador 28
PK - Pakistan 23
UZ - Uzbekistan 23
VE - Venezuela 23
CO - Colombia 20
MA - Marocco 18
AE - Emirati Arabi Uniti 13
PY - Paraguay 12
EG - Egitto 11
SA - Arabia Saudita 11
AL - Albania 10
IE - Irlanda 10
KE - Kenya 10
MY - Malesia 10
RO - Romania 10
AU - Australia 9
CL - Cile 9
JO - Giordania 9
UY - Uruguay 9
BO - Bolivia 8
CZ - Repubblica Ceca 8
NP - Nepal 8
PE - Perù 8
TN - Tunisia 8
CH - Svizzera 7
DZ - Algeria 7
IR - Iran 7
EU - Europa 6
IL - Israele 6
AZ - Azerbaigian 5
KR - Corea 5
LB - Libano 5
PH - Filippine 5
SY - Repubblica araba siriana 5
TH - Thailandia 5
DO - Repubblica Dominicana 4
JM - Giamaica 4
KG - Kirghizistan 4
NG - Nigeria 4
OM - Oman 4
PA - Panama 4
PS - Palestinian Territory 4
TT - Trinidad e Tobago 4
AM - Armenia 3
BA - Bosnia-Erzegovina 3
CR - Costa Rica 3
DK - Danimarca 3
GR - Grecia 3
LK - Sri Lanka 3
LV - Lettonia 3
TW - Taiwan 3
BG - Bulgaria 2
BY - Bielorussia 2
CY - Cipro 2
ET - Etiopia 2
GT - Guatemala 2
HN - Honduras 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
MD - Moldavia 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
QA - Qatar 2
SV - El Salvador 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BH - Bahrain 1
BW - Botswana 1
EE - Estonia 1
Totale 30.765
Salva come PNG Salva come JPEG
Città #
Singapore 2.058
Ashburn 1.554
Woodbridge 1.317
Fairfield 1.155
Chandler 1.111
Jacksonville 897
Santa Clara 814
Houston 803
Beijing 799
Hong Kong 777
Ann Arbor 506
Wilmington 443
Seattle 442
Cambridge 359
Munich 318
Los Angeles 299
New York 285
Izmir 279
Dallas 276
Nanjing 265
Princeton 227
Addison 216
Warsaw 201
Milan 155
San Diego 154
Shanghai 147
Ho Chi Minh City 143
Ferrara 142
São Paulo 135
Helsinki 125
Mexico City 120
Boardman 116
Hanoi 111
Turku 91
Jakarta 87
Shenyang 78
London 71
Hebei 70
Nanchang 70
Hefei 69
Washington 67
Bremen 66
Chicago 64
Tokyo 59
Brooklyn 58
Denver 58
Dearborn 56
Buffalo 55
Tianjin 55
Montreal 53
Changsha 52
Orem 52
Moscow 51
Chennai 48
Stockholm 47
Mountain View 46
Johannesburg 44
Jiaxing 43
Toronto 43
San Francisco 41
Boston 40
Rome 39
Phoenix 38
Falls Church 37
Atlanta 36
Bologna 36
Poplar 36
Redwood City 35
Brussels 34
Rio de Janeiro 34
Jinan 33
Kunming 33
Frankfurt am Main 31
Belo Horizonte 27
Guangzhou 27
Ankara 26
Manchester 26
Nuremberg 26
Ningbo 24
Norwalk 23
The Dalles 23
Zhengzhou 22
Falkenstein 21
Brasília 20
Campinas 19
San Jose 19
Des Moines 18
Ottawa 18
San Mateo 18
Curitiba 17
Haiphong 17
Modena 17
Tashkent 17
Amsterdam 16
Biên Hòa 15
Hangzhou 15
Hải Dương 15
Orange 15
Tappahannock 15
Auburn Hills 14
Totale 19.335
Salva come PNG Salva come JPEG
Nome #
Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds 285
Applicability of laparoscopic approach to the resection of large adrenal tumours: a retrospective cohort study on 200 patients 257
Effect of Everolimus on Cell Viability in Nonfunctioning Pituitary Adenomas 242
A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization 221
Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids 213
Recettori della somatostatina e carcinoma midollare della tiroide: prospettive future. 207
Circadian profile of plasma calcitonin gene-related peptide in healthy man 202
Predictors of Pituitary Dysfunction in Patients Surviving Ischemic Stroke 201
Effect of deltorphin on pituitary-adrenal response to insulin-induced hypoglycemia and ovine corticotropin-releasing hormone in healthy man 200
Acute lowering of plasma GH concentrations by somatostatin is associated with activation of pituitary-adrenal-axisin healthy young and elderly subjects 195
Circadian rhythm of calcitonin gene-related peptide in uncomplicated essential hypertension 193
Early onset acromegaly associated with a novel deletion in CDKN1B 5'UTR region 193
Protein Kinase C Delta restrains growth in ACTH-secreting pituitary adenoma cells 191
Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion 189
mTOR, AKT, p70S6K and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids 187
Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression 185
Activation of the somatotropic axis by testosterone in adult men: evidence for a role of hypothalamic growth hormone (GH)- releasing hormone function 175
Acute administration of human galanin in normal subjects reduces the potentiating effect of pyridostigmine-induced cholinergic enhancement on release of norepinephrine and pancreatic polypeptide 174
Efficacy and safety of the new 60 mg formulation of the long acting somatostatin analog lanreotide in the treatment of acromegaly. 174
Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression. 174
Growth hormone excess promotes breast cancer chemoresistance 174
X-linked acrogigantism syndrome: clinical profile and therapeutic responses 174
Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting Vascular Endothelial Growth Factor secretion 173
R171Q MEN1 polymorphism in patients presenting with hyperparathyroidism 173
Growth hormone induces chemoresistance in breast cancer cells 171
Antiproliferative effects of somatostatin analogs in pituitary adenomas 170
DELTA-OPIOID RECEPTOR MODULATION OF THE HYPOTHALAMIC -PITUITARY-ADRENOCORTICAL AXIS 170
Evaluation of hormonal function in a series of incidentally discovered adrenal masses 168
Therapeutic concentrations of mitotane (o,p′-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model 168
RET mutation profile and variable clinical manifestations in a family with multiple endocrine neoplasia type 2A and Hirschsprung's disease 168
Diurnal rhythm of plasma catecholamines in acromegaly 166
Unexpected activation of pituitary-adrenal axis in healthy young and elderly subjects during somatostatin infusion 166
Deletion of exons 1-3 of the MEN1 gene in a large Italian family causes the loss of menin expression 165
Neck paraganglioma and follicular lymphoma: A case report 163
A defective hypothalamic GHRH activity may contribute to declining GH secretion wuth age in man 162
Effects of octreotide on gallbladder motor function in acromegaly 162
Evidence that enhancement of cholinergic tone increases basal plasma levels of calcitonin gene-related peptide in normal man 160
Growth Hormone Enhances Breast Cancer Chemoresistance by Inhibiting JNK-Mediated Apoptosis 160
Pituitary side effects of old and new drugs. 160
A new VHL polymorphism in a big family from Ferrara 159
Recettori della Somatostatina e Carcinoma Midollare della Tiroide: prospettive future. 158
ADRENAL INCIDENTALOMA: CLINICAL AND METABOLIC ASPECTS DURING LONG-TERM FOLLOW-UP 157
In vitro testing of new somatostatin analogs on pituitary tumor cells 156
Atypical femoral fractures as a complication of long-term bisphosphonate therapy 155
Efficacy of tolvaptan treatment in a patient with syndrome of inappropriate antidiuresis (SIAD) after severe traumatic brain injury 155
Evaluation of bone markers and structure in subclinical Cushing’s syndrome 154
Prevalence and predictive factors of anterior hypopituitarism after ischemic stroke. 154
Efficacy and Safety of Teriparatide in Beta-Thalassemia Major Associated Osteoporosis: A Real-Life Experience 153
Cerebral aneurysm and acromegaly: a case report 153
Growth hormone and skeletal muscle function 153
Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS) 153
Cardiac and metabolic effects of chronic GH and IGF1 excess in young adults with pituitary gigantism 153
EFFECTS OF SOMATOSTATIN ANALOG TREATMENT ON GLUCOSE METABOLISM IN ACROMEGALY 151
GH enhances breast cancer chemoresistance by inhibiting JNK-mediated apoptosis 151
Hypopituitarism and growth hormone deficiency (GHD) after traumatic brain injury (TBI) 151
Effect of delta-opioid receptor agonist deltorphin on circulating concentrations of luteinizing hormone and follicle stimulating hormone in healthy fertile women 150
A tool to predict survival in stage IV entero-pancreatic NEN 150
Chromogranin A as a marker of neuroendocrine neoplasia: An Italian Multicenter Study 149
RISK FACTORS FOR DEVELOPING HYPOPITUITARISM AFTER STROKE 148
Blood GH-binding protein levels in premenopausal and postmenopausal women: role of body weight and estrogen levels 146
Efficay and safety of everolimus in metastatic gastroenteropancreatic neuroendocrine tumors 146
Post-stroke inflammatory response may influence pituitary function in patients with brain ischemic and hemorrhagic injury 146
Cyclo-oxygenase 2 modulates chemoresistance in breast cancer cells involving NF-κB 145
Efficacy, safety and adherence to treatment of teriparatide: an observational study 145
Le alterazioni pressorie nell'acromegalia: fattori umorali 144
Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame 144
Endogenous estrogen status significantly influences the nutrition-related alterations in Growth Hormone-Binding protein levles in healthy women 143
Growth Hormone enhances breast cancer chemoresistance by protecting from apoptosis 143
Functional hypothalamic and drug-induced amenorrhea: an overview 143
Dual-energy X-ray absorptiometry pitfalls in Thalassemia Major 143
Role of Piuitary Tumour Transforming Gene 1 in medullary thyroid carcinoma 142
GH influences breast cancer chemoresistanec independently of cell cycle perturbations 142
Delta opioid receptor involvement in endocrine pathophysiology 141
Glucose metabolism alterations in acromegaly 141
Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients 140
Inflammatory cytokines and neurotrophic factors correlate with pituitary function after stroke 140
Everolimus reduces human ACTH-secreting pituitary adenoma in vitro cell viability 138
Cerebrovascular disease and GH-IGF-i axis function 138
Lumbar spine mineral density Z-score discrepancy by DXA and QCT in thalassaemic major patients 138
Prevalence of hyopituitarism in post-acute and chronic phase of hemorrhagic stroke 137
ASSE GH-IGF-I NELL'INVECCHIAMENTO 136
Real-world study of everolimus in advanced progressive neuroendocrine tumors 136
Percutaneous Laser Ablation of Liver Metastases from Neuroendocrine Neoplasm. A Retrospective Study for Safety and Effectiveness 136
Everolimus reduces human ACTH secreting pituitary adenoma in vitro cell viability by inhibiting IGF-I down-stream signalling 135
ASYMPTOMATIC HYPERCALCITONINEMIA IN A PANCREATIC ENDOCRINE CARCINOMA ASSOCIATED WITH A PAPILLARY THYROID CANCER 135
Dopamine receptor 2 activation reduces cells viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion 134
Multiple somatostatin receptor subtypes activation reduces cell viability in non-functioning pituitary adenomas by inhibiting Vascular Endothelial Growth Factor secretion 133
Interrelationships between calcitonin gene-related peptide and sympathoadrenomedullary system: Effects of administration of epinephrine and norepinephrine in healthy man 132
Replacement therapy and quality of life improvement in adult GHD patients 132
Modulatory effect of the renin-angiotensin system on the plasma levels of calcitonin gene-related peptide in normal man 131
GH protects breast cancer cells from chemotherapy by blocking cytotoxic-induced apoptosis in estrogen receptor negative breast cancer cells 130
Ovarian tumors secreting insulin 130
null 130
Prevalence of hypopituitarismin patients with cerebrovascular diseases 128
Apoplessie in una casistica di adenomi ipofisari 128
Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function. 128
Bone metastases frequency, distribution, clinical and imaging characteristics in neuroendocrine tumors: our experience 127
Somatostatin receptor subtype 1 selective activation in human growth hormone- and prolactin-secreting pituitary adenomas: effects on cell viability, growth hormone and prolactin secretion. 126
Follow-up dei pazienti sottoposti a terapia chirurgica per adenomi ipofisari non secernenti. 123
PKCδ plays an important in regulating human medullary thyroid carcinoma cell viability 123
Totale 15.892
Salva come PNG Salva come JPEG
Categoria #
all - tutte 149.209
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 11.120
Totale 160.329
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.242 0 0 0 0 0 212 64 235 66 269 288 108
2021/20221.981 58 208 114 57 89 90 96 90 79 162 187 751
2022/20232.357 234 221 90 310 328 341 127 205 282 26 119 74
2023/20241.350 108 142 73 41 102 263 48 150 45 30 31 317
2024/20255.557 157 149 427 183 640 580 206 198 906 687 782 642
2025/20268.528 1.472 611 1.302 1.891 2.491 761 0 0 0 0 0 0
Totale 31.118